97176 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#2FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE
#3CANINE ANTIBODY MUTANTS
#4ACTIVATABLE BISPECIFIC ANTI-CD89 AND ANTI-PD-L1 PROTEINS AND USES THEREOF
#5METHODS AND COMPOSITIONS FOR CANCER TREATMENT
#6BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOF
#7NOVEL COMBINATION AND USE OF ANTIBODIES
#8COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES
#9Methods for Standardizing Lectin Reagents, IgA1 Calibration Standards, and Quantitative Measurement of Galactose-Deficient IgA1 in Human Samples
#10NKG2D-NKP46 CELL ADAPTER MOLECULE AND USE THEREOF
#11FCeRI BINDING PROTEIN
#12Chimeric Antigen Receptor and Natural Killer Cells Expressing Same
#13HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#14METHODS OF TREATING CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING ANTI-FCRN ANTIBODIES
#15METHODS OF TREATING GRAVES’ DISEASE USING ANTI-FCRN ANTIBODIES
#16EQUINE ANTIBODY MUTANTS
#17BISPECIFIC CD16A BINDERS
#18GLYCOENGINEERED POLYPEPTIDES TARGETING IMMUNOGLOBULIN A AND COMPLEXES COMPRISING THE SAME
#19ANTIBODIES FOR PLATELET FCyRIIA AND RELATED METHODS OF USE
#20FC FRAGMENTS THAT BIND FCRN AND METHODS OF USE
#21BISPECIFIC ANTIBODIES PROMOTE NATURAL KILLER CELL-MEDIATED ELIMINATION OF HIV-1 RESERVOIR CELLS
#22COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCERS
#23IMMUNOTHERAPY TARGETING TUMOR TRANSPOSABLE ELEMENT DERIVEDNEOANTIGENIC PEPTIDES IN GLIOBLASTOMA
#24METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)
#25HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#26BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view
#27METHODS FOR TREATING PRIMARY SJOGREN'S SYNDROME USING FCRN ANTAGONISTS
#28IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
#29COMPOSITIONS AND METHODS FOR THE TREATMENT OF VEN/AZA RESISTANT ACUTE MYELOID LEUKEMIA
#30HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#31ANTIGEN-BINDING MOLECULE FOR PROMOTING ELIMINATION OF ANTIGENS
#32ANTI-CD16A ANTIBODIES AND METHODS OF USE THEREOF
#33ANTIBODY MONO-OR MULTI-SPECIFIC TO EPHRIN TYPE-A RECEPTOR 10, CHIMERIC ANTIGEN RECEPTOR T-CELL EXPRESSING THE SAME AND USES THEREOF
#34METHODS FOR VACCINATION OF A SUBJECT TREATED WITH AN FCRN ANTAGONIST
#35CD16A Antibodies and Methods of Use
#36SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME
#37MEDICAMENTS, USES AND METHODS
#38THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE MYELOMA
#39NOVEL ANTAGONISTIC ANTI-TNFR2 ANTIBODIES
#40SUBCUTANEOUS FCRN ANTAGONIST FORMULATIONS AND METHODS OF USE THEREOF
#41FCRN/HSA BINDING MOLECULES AND METHODS OF USE
#42ANTIBODY OR FRAGMENT THEREOF THAT BINDS TO FCRL1
#43Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
#44FCRN ANTAGONIST MOLECULES AND METHODS OF USE THEREOF
#45COMPOSITIONS AND METHODS FOR NON-GENOTOXIC CONDITIONING
#46METHODS FOR TREATING LUPUS NEPHRITIS USING FCRN ANTAGONISTS
#47CROSSLINKING MULTISPECIFIC ANTIBODIES
#48FcRn-Binding Polypeptides and Uses Thereof
#49TUMOR NEOANTIGENIC PEPTIDES AND USES THEREOF
#50SYSTEM AND METHOD FOR THE DEVELOPMENT OF CD30 BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY OF CD30+ MALIGNANCIES
#51ANTI-FCRN ANTIBODIES
#52CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION
#53METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
#54SINGLE-DOMAIN HIGH AFFINITY ANTIBODIES AND METHODS OF USE THEREOF
#55ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#56FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE
#57PLANT-DERIVED THERAPEUTIC MONOCLONAL ANTIBODIES AND THEIR USE IN PREGNANT WOMEN
#58COMBINATION OF A FcyRIIB- AND A TUMOR ANTIBODY FOR USE IN THE TREATMENT OF AN FcyRIIB-NEGATIVE CANCER
#59DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
#60Binders of Chondroitin Sulfate Proteoglycan (CSPG4) Polypeptides
#61DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#62INTERLEUKIN-15 SUPERAGONIST N-803 IN PEOPLE EXPERIENCING LONG COVID
#63NK ENGAGER MOLECULES AND METHODS OF USE THEREOF
#64METHODS AND COMPOSITIONS FOR TREATING BARTH SYNDROME
#65IMMUNOTHERAPY TARGETING TUMOR TRANSPOSABLE ELEMENT DERIVED NEOANTIGENIC PEPTIDES IN GLIOBLASTOMA
#66RECOMBINANT T CELL RECEPTORS
#67ANTI-CD16A ANTIBODY AND APPLICATION THEREOF
#68INHIBITING MAST CELL ACTIVATION BY BINDING SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN-9 (SIGLEC-9)
#69ANTI-CD307E SINGLE-DOMAIN ANTIBODIES, USES THEREOF IN CAR T-CELL AND FOR THE TREATMENT OF DISEASES
#70ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
#71STABLE Fc FRAGMENTS, CONJUGATES, COMPOSITIONS, AND METHODS OF USE
#72METHODS AND COMPOSITIONS FOR RE-DOSING AAV USING ANTI-CD40 ANTAGONISTIC ANTIBODY TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE
#73METHODS OF TREATING RESPIRATORY DISORDERS
#74STABILIZED IGG4 ANTIBODIES AND USES THEREOF
#75METHODS TO MANIPULATE ALPHA-FETOPROTEIN (AFP)
#76BISPECIFIC BINDING AGENT
#77TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE ANTIBODIES AND USES THEREOF
#78APTAMER BASED AFFINITY CAPTURE METHODS FOR THE SELECTIVE ENRICHMENT OF HUMAN IMMUNOGLOBULIN FC DOMAINS
#79METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#80AGENTS FOR TREATMENT OF ENDOMETRIOSIS AND OTHER BENIGN GYNECOLOGICAL NEOPLASMS
#81COMPOSITIONS AND METHODS FOR THE TREATMENT OF VEN/AZA RESISTANT ACUTE MYELOID LEUKEMIA
#82HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#83METHODS AND COMPOSITIONS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOUS (SLE)
#84BIFUNCTIONAL DEGRADERS OF GALACTOSE-DEFICIENT IMMUNOGLOBULINS
#85ANTI-FCRN ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF WITH IMPROVED STABILITY
#86PH-DEPENDENT HSA-BINDING MOLECULES AND METHODS OF USE
#87MULTISPECIFIC NK ENGAGER PROTEIN
#88COMPOSITIONS AND METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA
#89ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#90MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16, AND METHODS OF USE
#91GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
#92ANTIGEN TARGETING, ANTI-CD16A, AND IMMUNE EFFECTOR CELL ACTIVATING TRIFUNCTIONAL FUSION PROTEIN, AND APPLICATION THEREOF
#93COMBINATIONS OF IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS AND FCRH5XCD3 BISPECIFIC ANTIBODIES FOR THE TREATMENT OF BLOOD CANCERS
#94ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
#95FC FRAGMENTS THAT BIND FCRN AND METHODS OF USE
#96ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
#97Anti-SIRPa Antibodies and Methods of Use Thereof
#98DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
#99Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
#100MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE
#101FUSION PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#102IL-15-BASED FUSIONS TO IL-12 AND IL-18
#103HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF
#104B7-H3 TARGETING FUSION PROTEINS AND METHODS OF USE THEREOF
#105BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY
#106ANTIBODIES SPECIFICALLY RECOGNIZING FCRN AND USES THEREOF
#107DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
#108FCRN BINDING MOLECULES AND METHODS OF USE
#109IGG1 FC MONOMER AND APPLICATION THEREOF
#110ANTIBODY OPTIMIZATION
#111COMPOSITIONS AND METHODS FOR CROSSLINKING FC RECEPTORS
#112FCRN ANTAGONISTS AND METHODS OF USE
#113METHODS FOR TREATING MYOSITIS USING FCRN ANTAGONISTS
#114MUC1 and CD16A Antibodies and Methods of Use
#115AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES
#116CYSTEINE PEPTIDE-ENABLED ANTIBODIES
#117CHIMERIC ANTIGEN RECEPTORS TARGETING FC RECEPTOR-LIKE 5 AND USES THEREOF
#118CD33-Binding Polypeptides and Uses Thereof
#119METHODS FOR TREATING BULLOUS PEMPHIGOID USING FCRN ANTAGONISTS
#120TARGETED REGULATION OF PLATELET AND MEGAKARYOCYTE ACTIVATION BY HETERORECEPTOR CO-CLUSTERING
#121Antibody Variants
#122HUMANIZED MOUSE MODELS OF THE FCRN RECYCLING PATHWAY
#123FCRN ANTAGONISTS FOR TREATMENT OF IGG-RELATED DISEASES AND DISORDERS
#124ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
#125DUAL TARGETING OF PEDIATRIC MALIGNANCIES THROUGH CAR T-CELLS SECRETING BISPECIFIC INNATE IMMUNE CELL ENGAGERS (BICES)
#126ANTI-BCMA NANOBODY AND USE THEREOF
#127ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES
#128FELINE ANTIBODY VARIANTS
#129ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR
#130IL-15-based fusions to IL-12 and IL-18
#131MULTI-SPECIFIC LIGAND BINDERS
#132FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED COMPLEMENT BINDING
#133COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
#134MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2
#135BISPECIFIC CD16A BINDERS
#136Method for the generation of genetically modified NK cells
#137PHARMACEUTICAL COMPOSITIONS FOR ANTIBODIES AND MAKING AND USING THE SAME
#138MULTISPECIFIC PROTEINS BINDING TO NKP46, A CYTOKINE RECEPTOR, A TUMOUR ANTIGEN AND CD16A
#139ANTIGEN TARGETING, ANTI-CD16A, AND IMMUNE EFFECTOR CELL ACTIVATING TRIFUNCTIONAL FUSION PROTEIN, AND APPLICATION THEREOF
#140HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE
#141DUPLEXBODIES
#142METHODS FOR TREATING PATIENTS WITH AN AUTOANTIBODY-MEDIATED DISEASE
#143MOLECULES FOR MODULATING THE IMMUNE SYSTEM AND USES THEREOF
#144PROTEINS BINDING NKG2D, CD16 AND BAFF-R
#145ORTHOGONAL MULTIMERIC PROTEINS
#146COMBINATION CANCER THERAPY WITH MEMORY NK CELLS AND ANTI-CANCER BISPECIFIC MOLECULES
#147ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a
#148METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES
#149CD16 ANTIBODY AND USE THEREOF
#150TISSUE-DIRECTED ANTIBODIES AND METHODS OF USING THE SAME
#151MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOF
#152CHIMERIC ANTIGEN RECEPTOR (CAR)-T SIGNALING OPTIMIZATION FOR TUNING ANTIGEN ACTIVATION THRESHOLD
#153SUBCUTANEOUS UNIT DOSAGE FORMS
#154CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#155Anti-VEGF protein compositions and methods for producing the same
#156NK CELL ENGAGER MOLECULES AND METHODS OF USE
#157Anti-VEGF protein compositions and methods for producing the same
#158Anti-SIRPα antibodies and methods of use thereof
#159IMPROVING ANTIBODY TOLERABILITY ASSOCIATED WITH INTRAVENOUS ADMINISTRATION
#160ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#161USES OF NK CELL ENGAGING ANTIBODY FUSION CONSTRUCTS FOR TREATMENTS
#162HETERODIMERIC Fc VARIANTS SELECTIVE FOR Fc GAMMA RIIB
#163ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
#164ARMED NK CELLS FOR UNIVERSAL CELL THERAPY
#165BINDING MOLECULES SPECIFIC FOR FCGAMMA RIIA AND USES THEREOF
#166FORMULATION FOR ANTI-FCRN ANTIBODY
#167COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
#168DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM)
#169INDUCED NK CELLS RESPONSIVE TO CD3/TAA BISPECIFIC ANTIBODIES
#170PROTEINS BINDING NKG2D, CD16 AND BAFF-R
#171ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFE
#172HETERODIMERIC FC DOMAIN ANTIBODIES
#173MULTI-SPECIFIC ANTIBODY CONSTRUCTS AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ED)
#174BISPECIFIC ANTIBODIES AND USE THEREOF
#175BISPECIFIC NK CELL AGONIST, PREPARATION METHOD, AND APPLICATION
#176BIFUNCTIONAL CHELATORS AND CONJUGATES
#177IL-15-BASED FUSIONS TO IL-12 AND IL-18
#178TARGETED REDUCTION OF ACTIVATED IMMUNE CELLS
#179CO-STIMULATORY MULTISPECIFIC ANTIBODIES
#180MODIFIED FCRN BINDING FRAGMENTS WITH IMPROVED HALF-LIFE
#181COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#182COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#183IMMUNE CELL PROLIFERATION/ACTIVATION KIT AND IMMUNE CELL CULTURE METHOD USING SAME PROLIFERATION/ACTIVATION KIT
#184PROTEINS BINDING HER2, NKG2D AND CD16
#185METHODS FOR REDUCING MATERNAL AUTOANTIBODIES
#186FC-DERIVED POLYPEPTIDES
#187POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE
#188IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY
#189CHIMERIC RECEPTOR FOR IMPROVING KILLING ACTIVITY OF IMMUNE CELLS AND APPLICATION THEREOF
#190MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING
#191MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
#192MOLECULES THAT BIND TO CD66e POLYPEPTIDES
#193MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN FOR ACTIVATION OF NATURAL KILLER CELLS AND THERAPEUTIC USES THEREOF TO TREAT CANCER
#194GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
#195COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#196COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#197DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Ra2 AND METHODS OF USE IN CANCER THERAPEUTICS
#198FCRN ANTIBODIES AND METHODS OF USE THEREOF
#199FcRn Antibodies and Methods of Use Thereof
#200COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS
#201NATURAL KILLER CELL ANTIBODIES WITH INCREASED ADCC ACTIVITY
#202ANTI-NKP30 ANTIBODY AND APPLICATION THEREOF
#203CANNABIS PREVENTS NK INACTIVATION IN CANCER AND INCREASES NK FUNCTION
#204MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#205PROTEINS BINDING NKG2D, CD16, AND CEACAM5
#206FC RECEPTOR BINDING PROTEINS
#207MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#208MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#209PROTEINS BINDING NKG2D, CD16 AND FLT3
#210TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS
#211ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
#212SINGLE-DOMAIN ANTIBODY AGAINST CD16A AND USE THEREOF
#213IL-15-based fusions to IL-12 and IL-18
#214ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS
#215ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES
#216NOVEL COMBINATIONS OF ANTIBODIES AND USES THEREOF
#217AN AGR2Xcd3 BISPECIFIC ENGAGER FOR THE TREATMENT OF CANCER
#218HER2 ANTIBODY AND APPLICATION THEREOF
#219Antibody variable domains targeting the NKG2D receptor
#220Antibody variable domains targeting the NKG2D receptor
#221FCRN BINDING POLYPEPTIDES
#222ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#223Antibody variable domains targeting the NKG2D receptor
#224FELINE ANTIBODY VARIANTS
#225Anti-VEGF protein compositions and methods for producing the same
#226DUAL-SPECIFIC APTAMER TRIGGERING CELL-MEDIATED CYTOTOXICITY TO LYSE HER2-POSITIVE CANCER CELLS
#227MUTATIONS IN CANINE ANTIBODY CONSTANT REGIONS
#228PREVENTION OR MITIGATION OF NK CELL ENGAGING AGENT-RELATED ADVERSE EFFECTS
#229Bifunctional chelators and conjugates
#230IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
#231Fc-Receptor CAR Constructs and Cells
#232MOLECULES THAT BIND TO MESOTHELIN POLYPEPTIDES
#233PROTEINS BINDING CD123, NKG2D AND CD16
#234DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES
#235METHOD FOR TREATING SJOGREN'S SYNDROME USING TACI-FC FUSION PROTEIN
#236GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
#237METHODS AND COMPOSITIONS FOR DEPLETING NATURAL KILLER CELLS AND USES THEREOF IN CELLULAR THERAPIES
#238METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND HER2
#239IMMUNOSILENCING Fc VARIANTS
#240HETERODIMER FC POLYPEPTIDE
#241ANTIGEN-BINDING FRAGMENTS AND USES THEREOF
#242USE OF FcgammaRIII INHIBITOR IN PREPARATION OF MEDICAMENT FOR TREATING PULMONARY FIBROSIS
#243PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE
#244ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL
#245FC ALPHA RECEPTOR BINDING ANTIBODY
#246VISTA AGONIST FOR TREATMENT/PREVENTION OF ISCHEMIC AND/OR REPERFUSION INJURY
#247MULTISPECIFIC BINDING PROTEINS TARGETING CEA
#248Anti-FcRn antibody or antigen binding fragment thereof with improved stability
#249POLYFUNCTIONAL ORTHOGONAL PROTEIN CHIMERAS
#250Antigen binding receptors specific for mutated Fc domains
#251Covalent Diabodies and Uses Thereof
#252COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES
#253INTERLEUKIN-21 MUTEIN/ ANTI-PD-1 ANTIBODY CONJUGATES
#254GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
#255TRISPECIFIC BINDERS
#256IMMUNOSILENCING Fc VARIANTS
#257COMPOSITION FOR ANTIVIRUS COMPRISING NATURAL KILLER CELL
#258PROTEINS BINDING NKG2D, CD16 AND NECTIN4
#259Anti-VEGF protein compositions and methods for producing the same
#260Methods and means for the production of Ig-like molecules
#261Methods and compositions for transducing lymphocytes and regulating the activity thereof
#262Vaccine Compositions and Antibodies For Lyme Disease
#263ANTI-FC EPSILON-R1 ALPHA (FCER1A) ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND FCER1A AND CD3, AND USES THEREOF
#264ANTIBODY CONSTRUCTS TO TARGET T CELL RESPONSES TO SARS-COV PROTEIN EXPRESSING CELLS, THEIR DESIGN AND USES
#265Anti-VEGF protein compositions and methods for producing the same
#266MODEL FOR PREDICTION OF TOLERABILITY ISSUES IN CONNECTION WITH INTRAVENOUS ADMINISTRATION OF THERAPEUTIC ANTIBODIES
#267PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR
#268SYSTEM AND METHOD FOR THE DEVELOPMENT OF CD30 BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY OF CD30+ MALIGNANCIES
#269SIGNAL PEPTIDE FOR REDUCING END HETEROGENEITY OF HETEROLOGOUS POLYPEPTIDE
#270CD33-binding polypeptides and uses thereof
#271NUCLEIC ACIDS ENCODING A POLYPEPTIDE COMPRISING A MODIFIED FC REGION OF A HUMAN IGG1 AND AT LEAST ONE HETEROLOGOUS ANTIGEN
#272COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
#273APTAMER BASED AFFINITY CAPTURE METHODS FOR THE SELECTIVE ENRICHMENT OF HUMAN IMMUNOGLOBULIN FC DOMAINS
#274Binding molecules against BCMA and uses thereof
#275COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN CANINES AND METHODS OF USE
#276MODIFIED J-CHAIN
#277Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules
#278Anti-VEGF protein compositions and methods for producing the same
#279MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#280Anti-TMPRSS2 antibodies and antigen-binding fragments
#281METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#282PROTEINS BINDING NKG2D, CD16 AND EGFR
#283IMMUNITY ENHANCING AGENT FOR CANCER BY ALLERGIN-1 ANTAGONIST
#284IL-15-based fusions to IL-12 and IL-18
#285ACE2-FC FUSION PROTEINS AND METHODS OF USE
#286ENGINEERED IMMUNOGLOBULINS
#287Humanized Anti-Human CD89 Antibodies and Uses Thereof
#288COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS
#289BISPECIFIC IMMUNE CELL ENGAGERS WITH BINDING SPECIFICITY FOR HLA-G AND ANOTHER ANTIGEN
#290ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES
#291Anti-VEGF protein compositions and methods for producing the same
#292COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
#293Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using
#294METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
#295NEW ANTIBODY BLOCKING HUMAN FCGRIIIA AND FCGRIIIB
#296ANTIBODIES WITH MODIFIED AFFINITY TO FCRN THAT PROMOTE ANTIGEN CLEARANCE
#297METHOD OF CULTURING NK CELLS AND KITS CONTAINING MEDIUM ADDITIONS
#298B7H3-TARGETING PROTEINS AND METHODS OF USE THEREOF
#299Methods and compositions for antibody to high affinity receptor for IgE
#300FC VARIANT AND PREPARATION THEREOF